Synairgen Developing COPD Treatment To Hold Off Further Viral Damage
Executive Summary
UK-based biotech Synairgen spoke to Scrip about the development of its COPD therapy, which is for patients whose lung disease has been exacerbated by the cold or influenza virus.
You may also be interested in...
AstraZeneca Ends AZD9412 IFN-β Asthma Trial For Redesign, Relaunch
AstraZeneca is stopping a Phase IIa trial assessing in-licensed AZD9412's effect on asthma patients because fewer of them than expected had their condition worsen, making it difficult for the respiratory specialist to gauge the drug's efficiency. AstraZeneca will now re-design the endpoints and resume the study in 2017.
Synairgen, Pharmaxis Pair Up On LOXL2 Lung Disease Therapy
UK biotechnology company Synairgen plc is teaming up with Australian pharmaceutical company Pharmaxis Ltd to develop a new drug for idiopathic pulmonary fibrosis (IPF) which it hopes to pair up with a big pharma on later down the line.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.